Legal Representation
Attorney
Alexandra MacKay
USPTO Deadlines 2 active
| Deadline Type | Event Code | Deadline Date | Days Until | Priority | Extension Available |
|---|---|---|---|---|---|
|
MAINTENANCE
Section 8 (6-Year) Declaration Due (Based on registration date 2025-01-28) |
R.PRA | Jan 28, 2031 | 2031 days | Critical | No |
|
MAINTENANCE
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2025-01-28) |
R.PRA | Jan 28, 2035 | 3492 days | Critical | No |
Next deadline: Section 8 (6-Year) Declaration Due (Based on registration date 2025-01-28)
on January 28, 2031
(2031 days)
Application History
19 events| Date | Code | Type | Description |
|---|---|---|---|
| Jan 28, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jan 28, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Dec 10, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Dec 10, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Dec 4, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Oct 9, 2024 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Oct 9, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Aug 6, 2024 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Jul 23, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jul 22, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jul 22, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jul 22, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jun 13, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jun 13, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jun 13, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jun 9, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Nov 2, 2023 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Nov 1, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Oct 30, 2023 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; Biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes
Class 042
Medical, scientific and industrial research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; Pharmaceutical drug development services
Class 044
Medical services; providing medical and pharmaceutical advice; gene bank services
Active Deadlines
Section 8 (6-Year) Declaration Due (Based on registration date 2025-01-28)
Due: Jan 28, 2031
Grace Period Until: Jul 28, 2031
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2025-01-28)
Due: Jan 28, 2035
Grace Period Until: Jul 28, 2035
Additional Information
Design Mark
The mark consists of a predominantly rectangular field, containing a curved line and a convex bottom side filled with the gradient composed of orange, teal, and turquoise.
Color Claim
The colors orange, teal, and turquoise are claimed as a feature of the mark.
Classification
International Classes
005
042
044